<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02423096</url>
  </required_header>
  <id_info>
    <org_study_id>103-0721C</org_study_id>
    <nct_id>NCT02423096</nct_id>
  </id_info>
  <brief_title>Neuroendocrine and Metabolite Substrates in Schizophrenia</brief_title>
  <official_title>Neuroendocrine, Metabolite Substrates, Clinical Symptoms and Cognitive Function in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Schizophrenia is a serious mental illness. The diagnosis and severity evaluations&#xD;
      of schizophrenia are generally based on patient behaviors. Biomarkers are objectively&#xD;
      measured and used as indicators for diagnosis confirmation, symptom assessment, and&#xD;
      evaluation of pharmacologic responses to therapeutic interventions. Neuroendocrine and&#xD;
      metabolite substrates are potential biomarkers of the pathogenic processes in schizophrenia.&#xD;
&#xD;
      Aims: The aims of this study are to determine (a) the differences in neuroendocrine and&#xD;
      metabolite substrates between patients diagnosed with schizophrenia and healthy controls; and&#xD;
      (b) the associations among the neuroendocrine and metabolite substrates, cognitive function,&#xD;
      clinical symptoms, and treatment responses of patients diagnosed with schizophrenia.&#xD;
&#xD;
      Methods: (a) The investigators plan to recruit 100 patients diagnosed with schizophrenia and&#xD;
      100 healthy controls as participants. (b) At the baseline and Week 12, patient blood samples&#xD;
      will be obtained to measure the levels of neuroendocrine substrates and metabolite markers.&#xD;
      Clinical symptoms and cognitive function will be evaluated. (c) For the healthy control&#xD;
      participants, blood samples will be obtained once to measure neuroendocrine and metabolite&#xD;
      marker levels.&#xD;
&#xD;
      Expected Results: The results of this study may contribute to identifying potential&#xD;
      neuroendocrine and metabolite biomarkers of schizophrenia, and clarify the associations among&#xD;
      the neuroendocrine and metabolite substrates, cognitive function, clinical symptoms, and&#xD;
      treatment responses of patients diagnosed with schizophrenia. Such information is crucial for&#xD;
      clinical evaluations and future research.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. The investigators plan to recruit 100 patients with schizophrenia and 100 healthy&#xD;
           control subjects.&#xD;
&#xD;
        2. For the patients, diagnoses of schizophrenia will be confirmed using the Chinese version&#xD;
           of the Mini International Neuropsychiatric Interview (MINI). At the baseline and Week&#xD;
           12, patient blood samples will be obtained to measure the levels of neuroendocrine&#xD;
           substrates (didehydroepiandrosterone, dehydroepiandrosterone sulfate, pregnenolone, and&#xD;
           cortisol) and metabolite markers (lipid profiles, glycerate, eicosenoic acid, pyruvate,&#xD;
           b-hydroxybutyrate, Cysteine). Cognitive function will be evaluated using the Brief&#xD;
           Assessment of Cognition in Schizophrenia. The participants' clinical symptoms and daily&#xD;
           activities will be assessed using the Positive and Negative Syndrome Scale, 17-item&#xD;
           Hamilton Depression Rating Scale, and Personal and Social Performance Scale.&#xD;
&#xD;
        3. For the healthy control subjects, psychiatric diagnoses will be verified using MINI, and&#xD;
           blood samples will be obtained once to measure neuroendocrine and metabolite marker&#xD;
           levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Weeks</target_duration>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale</measure>
    <time_frame>Participants will be assessed at the outpatient department, an expected average of 30 min.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Assessment of Cognition in Schizophrenia</measure>
    <time_frame>Participants will be assessed at the outpatient department, an expected average of 40 min.</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Schizophrenia</arm_group_label>
    <description>Patients with schizophrenia will be treated with antipsychotic drugs as routine care (i.e., risperidone, haloperidol, sulpiride, olanzapine, quetiapine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>No special intervention will be provided for healthy controls.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Patients with schizophrenia will be treated with antipsychotic drugs as routine care.</description>
    <arm_group_label>Schizophrenia</arm_group_label>
    <other_name>Haloperidol</other_name>
    <other_name>Sulpiride</other_name>
    <other_name>Olanzapine</other_name>
    <other_name>Quetiapine</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples of patients and control subjects will be obtained to measure the levels of&#xD;
      neuroendocrine substrates (didehydroepiandrosterone, dehydroepiandrosterone sulfate,&#xD;
      pregnenolone, and cortisol) and metabolite markers (lipid profiles, glycerate, eicosenoic&#xD;
      acid, pyruvate, b-hydroxybutyrate, Cysteine)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Patients with schizophrenia will be recruited from the out-patient department in&#xD;
             Kaohsiung Chang Gung Memorial Hospital, Kaohsiung city, Taiwan&#xD;
&#xD;
          2. Healthy controls will be recruited from the staff in Kaohsiung Chang Gung Memorial&#xD;
             Hospital and from the communities in Kaohsiung city, Taiwan&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients with Schizophrenia&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          1. Diagnosed with schizophrenia and will be confirmed using the Chinese version of the&#xD;
             Mini International Neuropsychiatric Interview (MINI).&#xD;
&#xD;
          2. Age between 18 to 79.&#xD;
&#xD;
          3. Have signed the informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        1. Having history of illicit drug use or other major psychiatric disorders (e.g., bipolar&#xD;
        disorder, major depressive disorder, or organic mental disorders).&#xD;
&#xD;
        Healthy Controls&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          1. Psychiatric diagnosis without schizophrenia will be confirmed using the Chinese&#xD;
             version of MINI.&#xD;
&#xD;
          2. Age between 18 to 79.&#xD;
&#xD;
          3. Have signed the informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        1. Having history of illicit drug use or other major psychiatric disorders (e.g.,&#xD;
        psychosis, bipolar disorder, major depressive disorder, or organic mental disorders).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang-Jen Wang, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital, Kaohsiung, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liang-Jen Wang, MD, MPH</last_name>
    <phone>886-7-7317123</phone>
    <phone_ext>6319</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Liang-Jen Wang</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>April 15, 2015</study_first_submitted>
  <study_first_submitted_qc>April 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Wang Liang-Jen</investigator_full_name>
    <investigator_title>Associate Professor and Visiting Staff</investigator_title>
  </responsible_party>
  <keyword>biomarker</keyword>
  <keyword>neuroendocrine</keyword>
  <keyword>metabolite</keyword>
  <keyword>cognitive functioning</keyword>
  <keyword>clinical symptoms</keyword>
  <keyword>schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

